The week in pharma: action, reaction and insight – week to August 29
By Barbara Obstoj-Cardwell
Significant research news last week included Netherlands-based argenx, release of positive Phase III results for its myasthenia gravis (gMG) candidate Vyvgart, and Regeneron announcement of Phase III data on its cemdisiran and pozelimab, also for the treatment gMG. On the regulatory front, Amgen won US Food and Drug Administration (FDA) approval for its Repatha for the extended indication for patients at risk of major cardiovascular events. Also, of note, the FDA backed biomarkers for the development of metabolic dysfunction-associated steatohepatitis (MASH) clinical trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze